Eloralintide is an amylin analogue, the same pathway as cagrilintide: a hormone released with insulin that signals to the hindbrain that a meal has happened.
What draws attention to it is the size of the phase 2 result. Up to about 20% mean weight loss at 48 weeks, from a single agent, is in the territory that previously required a GLP-1 combination. Cagrilintide alone produced roughly half that. If it holds through phase 3 — it would make amylin a first-line mechanism — not a partner to GLP-1.
That caveat is doing real work. Phase 2 results in this field routinely shrink when repeated at scale, the trial was smaller and shorter than a registration programme, and phase 3 only began in late 2025. Nothing is approved, and what is sold as eloralintide today is a research chemical.
How it works
Eloralintide activates amylin and calcitonin family receptors in the hindbrain, producing satiety and slowing gastric emptying. It is the same signalling route the natural hormone uses after a meal.
That pathway is separate from GLP-1. Both end in reduced food intake, through different receptors in different brain regions. Which is why amylin analogues have mostly been developed as partners to GLP-1 drugs rather than as replacements.
Natural amylin cannot be used as a drug because it aggregates into fibrils in solution. Every amylin analogue is engineered around that problem, and the engineering is what distinguishes them from one another.
A single agent producing GLP-1-scale weight loss through amylin alone would be a change in how the whole category is built. That is the claim phase 3 has to support.
Regulatory status — United States
Not approved anywhere. Phase 2 is complete and phase 3 began in late 2025. Anything sold as eloralintide is a research chemical produced outside the controls a future approval would rest on.
Last reviewed 18 Aug 2026. Regulatory positions in this category change frequently; we date this line so you can see how current it is.
What it is studied for
Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.
Weight management
Clinical trialThe purpose it is being developed for.
EvidenceA phase 2 trial reported up to approximately 20% mean weight loss at 48 weeks depending on dose. Phase 3 began in late 2025 and has not reported.
Identity and clearance
Molecule
- Class
- Amylin receptor agonist, acylated analogue
Pharmacokinetics
Clinical trialWeekly dosing.
Dose protocols reported in sources
Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.
| Goal | Dose | Frequency | Route | Units, 5 mg vial | Source | Start this protocol |
|---|---|---|---|---|---|---|
| Phase 2 dose range | 1 mg – 3 mg | Once weekly, reached by escalation | SubcutaneousEscalated over several weeks. The largest weight loss came from the highest doses, and so did the nausea. That trade-off defines the class. | 20–60 u | Clinical trial | Start this |
Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.
Calculator
Work out what to draw
Pre-filled with a 5 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.
Draw to 60 units on a 1 mL U-100 syringe. That is 0.6 mL, containing 3 mg of Eloralintide.
60 units sits exactly on a printed line.
Bioalmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.
Open this calculation in the full calculator
Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.
Safety
Reported effects
- Nausea and vomitingClinical trial
Very common in trials
Dose-related, and the reason the largest doses are not simply the best choice.
- Reduced appetite to the point of inadequate intakeClinical trial
Reported at higher doses
Weight loss of this size over 48 weeks makes eating enough protein a practical problem, not a theoretical one.
- Injection site reactionsClinical trial
Common
- Anything beyond 48 weeksClinical trial
Unknown
Phase 2 is the longest completed trial. Nothing establishes what longer use does.
When to stop
- Vomiting severe enough that you cannot keep fluids down.
- Losing weight faster than roughly 1% of body weight per week, or being unable to eat adequately.
- Severe, persistent abdominal pain.
- Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
Interactions and situations that need care
- Pregnancy and breastfeedingAvoid
No safety data, and weight loss in pregnancy is contraindicated.
- Gastroparesis or severe gastrointestinal diseaseUse caution
Slowed gastric emptying is part of the mechanism, which makes an existing motility disorder worse.
- Insulin or sulfonylurea therapyUse caution
Amylin suppresses glucagon, which lowers glucose. Stacking that with insulin causes hypoglycaemia, and those doses need adjusting by a prescriber.
- Treating the phase 2 figure as settledUse caution
Up to 20% from a single agent would be a genuine shift in this category. This is exactly why it needs phase 3 confirmation. Results of this size in phase 2 routinely shrink at scale.
What to expect
- Up to roughly 20% mean weight loss at 48 weeks in phase 2, a large number for a single agent on the amylin pathway.
- Phase 3 began in late 2025 and has not reported. Until it does, this is a promising phase 2 result, not an established one.
- It is not approved. What is sold under the name is a research chemical.
- Nausea is dose-related and is what limits the dose in practice.
Storage and handling
- Freeze-dried powder
- Refrigerated at 2–8 °C, protected from light.
- After mixing
- Refrigerated at 2–8 °C. Do not freeze once mixed.
- Long-term, frozen
- Unopened powder is stable at −20 °C or colder.
With other peptides
- Cagrilintideincompatible
Both are amylin receptor agonists. Running them together stacks one mechanism and its nausea rather than adding a second.
- Semaglutidecaution
Amylin and GLP-1 signal satiety through different receptors, which is the basis of the CagriSema combination. No trial has tested this pairing, and stacking two strong appetite suppressants risks intake falling below what is safe.
Checking your vial
Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it. More on assessing quality and COAs.
White cake, clear solution after gentle mixing
Standard for a lyophilised acylated peptide.
Cloudy or opalescent solution, or anything fibrous
Amylin analogues are engineered specifically to resist fibril formation. Strands or gel in the solution mean that has failed. Do not use it.
Questions
- How is it different from cagrilintide?
- Same pathway, different molecule, and a much larger phase 2 result: roughly 20% against cagrilintide's 10.8%. Cagrilintide is being developed as half of a combination; eloralintide's numbers suggest it might work alone.
- Is it better than semaglutide?
- The phase 2 number is larger. It is also phase 2, in a smaller and shorter trial, against semaglutide's completed registration programme and cardiovascular outcomes data. Those are not comparable levels of evidence.
References
Eloralintide in adults with overweight or obesity: phase 2 trial
Eli Lilly phase 2 programme, 2025 · Randomised, double-blind, placebo-controlled phase 2 trial
Adults with overweight or obesity · Escalating weekly subcutaneous doses · 48 weeks
Up to approximately 20% mean weight loss depending on dose. Nausea was dose-related and the most common adverse event. Phase 3 began in late 2025.
Related compounds
Cagrilintide
A long-acting amylin analogue in late-stage trials. It works on a different satiety pathway from the GLP-1 drugs. Which is why it is being developed alongside semaglutide rather than against it.
Semaglutide
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and for weight management, dosed once weekly.
Tirzepatide
A once-weekly dual agonist that activates both the GIP and GLP-1 receptors, approved for type 2 diabetes and for weight management.
Retatrutide
An investigational once-weekly triple agonist acting on the GLP-1, GIP and glucagon receptors. Not approved anywhere.
Next
What to do with Eloralintide
- Keep a record of itTurn a dose and a schedule into a protocol, then log what you actually take. Eloralintide is filled in for you.
- See what it costsPer-milligram prices read from vendor sites and confirmed by a person, so vial sizes compare.
- Check a combinationWhat our profiles record about Eloralintide alongside each other compound — including the pairs where nothing is recorded.
Keep this page honest
If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice. No clinician reviews these pages.
Page last updated 18 Aug 2026